GSK plies savings from green initiatives

GlaxoSmithKline ($GSK) appears to be gaining confidence as its sustainability initiatives gain momentum. Its next target: carbon neutrality across its value chain by 2050. That means no net greenhouse gas emissions from raw material sourcing, manufacturing, distribution, product use and disposal. The company estimates associated savings of $161 million per year by 2020.

GSK already has a noteworthy string of sustainability accomplishments 16 percent water use reduction since 2006; surpassed five-year targets for wastewater quality, waste volume and VOC emissions; 99.4-percent reduction in chlorofluorocarbons use.

The drug giant has also erected wind turbines at its Barnard Castle site and installed 11,000 solar panels on a regional distribution center in York, PA. The solar setup provides for all of the facility's power needs and saves 1,800 tons of CO2 per year.

- see the story
- here's more
- and read GSK's sustainability report

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.